- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03848039
Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9 (HOPE9)
A Randomised, Double-Blind, Placebo-Controlled, Phase III Study to Investigate the Efficacy of Presurgical 9-valent HPV Vaccination in Women Treated With LEEP for CIN 2+ and Initially Invasive Cervical Cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale:
In 2006 HPV vaccination was licensed for primary prevention programs worldwide. Only a few years after, several studies have raised new scenarios about HPV related diseases with strong implications on clinical management in adult women. Some findings from retrospective data have shown a significant effect of HPV vaccine on women and men treated for HPV pathologies. Although vaccination is not effective in patients with prevalent HPV infection, some studies have suggested that HPV vaccine could influence the incidence of the disease relapse after a surgical treatment. Reduction in disease recurrence after surgical treatment in vaccinated patients comes from gastroenterological, gynecological and dermatological evidences concerning both benign lesions (warts) and precancerous lesions.
If vaccination reduces recurrence rates by 80%, according to our previous pilot study data, peri-surgical HPV vaccination will be a strong effective clinical intervention, very likely to be introduced into standard high grade cervical intraepithelial neoplasia management.
Objective:
The primary objective of the current study is to assess the efficacy of 9-valent HPV vaccination in preventing recurrence of CIN2+ in participants treated for high-grade CIN.
Study population: participants treated for CIN2+ with LEEP technique. Study design: A multicenter, randomised, double-blind clinical trial in 9 hospitals in Italy.
Intervention: Participants will be randomized in a 1:1 ratio to receive presurgical 9-valent HPV vaccination (Gardasil-9 ®) or placebo at months 0 (at pre-surgical enrollment time), at 2 months (the same day of surgical treatment) and 6 moths (during the first follow-up visit after surgery). The randomization list will be generated before the start of the study.
Main study parameters/endpoints:
Primary end point will be the cumulative recurrence of CIN2+ after conization, as assessed by biopsies taken of suspect lesions, histologically confirmed for high grade cervical intraepithelial neoplasia recurrence.
Secondary outcome measures are cumulative incidence/persistence of HPV infection after the surgical treatment, causative HPV type in recurrent CIN lesions, as assessed by HPV test and PCR (polymerase chain reaction).
The total sample size is estimated to be 1220 patients based on an expected recurrence rate of less than 6% within 5 years. Statistical analysis will be based on the intention-to-treat protocol. Both primary and secondary endpoints will be analyzed by descriptive statistics and the chi-square test with a 0,05 two-sided significance level.
Follow-up schedule (FUP) will be the same in both arms, with a FUP evaluation every 6 months in the first year followed by an annual evaluation for a total of 5 years. FUP visit will include HPV test, Pap-test and colposcopy. HPV test will be collected in order to evaluate the HPV infection clearance rate in both arms. HPV test will be part of all the follow-up visits allowing to study the natural history of HPV infection after the surgical treatment.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Alessandro Ghelardi, MD
- Phone Number: +39 0585 6571
- Email: alessandro.ghelardi@uslnordovest.toscana.it
Study Contact Backup
- Name: Paola Bay, MD
- Phone Number: +39 0585 6571
- Email: paola.bay@uslnordovest.toscana.it
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged ≥ 18 and ecog performance status ≤ 1
- Patients with a diagnosis of high-grade cervical intraepithelial neoplasia or initially invasive cervical cancer (histological results ≥ CIN2 + and ≤ Ia1 according to the FIGO staging of cervical cancer)
- No fever at the time of vaccination
- No previous HPV vaccination
- Ability to understand and write Italian
- Signed informed and privacy consent
Exclusion Criteria:
- Patients enrolled in other clinical studies
- History of allergic reaction or serious adverse events to previous vaccinations
- Positive pregnancy test at the time of vaccination
- Patient in treatment with immunosuppressive therapy
- Subjects who received immunoglobulins or blood products in 3 months prior to vaccination.
- Thrombocytopenia or any other clotting disorder that may lead to bleeding as a result of intramuscular administration
- Clinical criteria contraindicating the surgical act of conization
- ECOG performance status ≥2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gardasil-9
Intramuscular Gardasil-9 vaccination at 0, 2 and 6 months.
|
administration by intramuscular injection of the 9-valent HPV vaccine according to a 3-dose vaccination schedule (0, 2, 6 months).
Other Names:
|
Placebo Comparator: Placebo
Placebo injection at 0, 2 and 6 months
|
administration by intramuscular injection of the placebo according to vaccination schedule of the 9-valent HPV vaccine (0, 2, 6 months)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
evaluation of disease recurrence reduction (cervical intraepithelial neoplasia up to microinvasive cancer of the cervix)
Time Frame: 5 years after surgical treatment
|
evaluation of disease recurrence reduction (cervical intraepithelial neoplasia up to microinvasive cancer of the cervix) by comparing the number of recurrences in the two arms of the study
|
5 years after surgical treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
impact of the vaccine on prevalent post-surgery infections
Time Frame: 5 years after surgical treatment
|
Analysis of the impact of the vaccine on prevalent post-surgery infections by comparing the prevalence of persistent HPV infections (duration greater than 12 months after surgery) in the two arms.
|
5 years after surgical treatment
|
impact of the vaccine in the post-surgical surveillance times, comparison of viral wash-out times (negativity of the HPV test), times of negativization of the pap test and of the colposcopic picture in the post-operative period
Time Frame: 5 years after surgical treatment
|
Analysis of the impact of the vaccine in the post-surgical surveillance times, comparison of the viral wash-out times (negativity of the HPV test), times of negativization of the pap test and of the colposcopic picture in the post-operative period: comparison of the times of negativization overexposed in the two arms.
|
5 years after surgical treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alessandro Ghelardi, MD, Az. USL Toscana Nord Ovest
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HOPE9 STUDY
- 2018-003507-19 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Intraepithelial Neoplasia
-
Krankenhaus Barmherzige Schwestern LinzMedical University of ViennaCompletedCervical Intraepithelial Neoplasia Grade 1 | Cervical Intraepithelial Neoplasia Grade 2Austria
-
National Cancer Institute (NCI)TerminatedCervical Cancer | Cervical Intraepithelial Neoplasia Grade 2 | Cervical Intraepithelial Neoplasia Grade 3United States
-
Genexine, Inc.CompletedCervical Intraepithelial Neoplasia 3Korea, Republic of
-
Nykode Therapeutics ASATheradex; Vaccibody ASCompletedHigh Grade Cervical Intraepithelial NeoplasiaGermany
-
University of Alabama at BirminghamNational Cancer Institute (NCI)CompletedHigh-grade Cervical Intraepithelial NeoplasiaUnited States
-
National Cancer Institute (NCI)Active, not recruitingCervical Intraepithelial Neoplasia Grade 2/3 | High Grade Cervical Intraepithelial Neoplasia | Cervical Squamous Cell Carcinoma In Situ | Cervical Squamous Intraepithelial Neoplasia 2United States
-
BioLeaders CorporationUnknownCervical Intraepithelial Neoplasia Grade 2/3Korea, Republic of
-
Brookdale University Hospital Medical CenterUnknownCarcinoma in Situ of Uterine Cervix | Cervical Intraepithelial Neoplasias | High Grade Cervical Intraepithelial NeoplasiaUnited States
-
University Medical Centre MariborRecruitingCervical Intraepithelial Neoplasia Grade 2 | DNA MethylationSlovenia
-
Onconix, IncUnknownCervical Cancer | Cervical Intraepithelial Neoplasia III | Cervical Intraepithelial Neoplasia IIUnited States
Clinical Trials on Gardasil-9
-
Laval UniversityCenters for Disease Control and PreventionCompletedHuman Papillomavirus VaccinesCanada
-
Western Institute for Veterans ResearchMerck Sharp & Dohme LLC; University of UtahRecruiting
-
London School of Hygiene and Tropical MedicineMerck Sharp & Dohme LLC; Public Health England; University of CambridgeActive, not recruitingHuman Papillomavirus VaccineGambia
-
Boston Medical CenterMerck Sharp & Dohme LLCRecruiting
-
Shanghai Zerun Biotechnology Co.,LtdWalvax Biotechnology Co., Ltd.Active, not recruitingCervical Cancer | Papillomavirus Infections | CIN | Genital Wart | VINChina
-
Centre Hospitalier Universitaire de la RéunionCompleted
-
Eastern Virginia Medical SchoolMerck Sharp & Dohme LLCRecruitingPapillomavirus VaccinesUnited States
-
University Health Network, TorontoMerck Sharp & Dohme LLCNot yet recruitingAnal Cancer | Human Papilloma Virus | Anal Intraepithelial NeoplasiaCanada
-
National Institute of Allergy and Infectious Diseases...RecruitingIdiopathic CD4 T Cell LymphocytopeniaUnited States